Biopharma Quarterly Dealmaking Statistics, Q4 2015
A look at financing, M&A, and alliance activity October-December 2015
Executive Summary
Biopharma financing for Q4 totaled $13.1 billion, a 35% increase over Q3, and again was dominated by follow-on public offerings. M&A reached a record $201 billion, topped by Pfizer's $160 billion buy of Allergan. Sanofi's $4.2 billion diabetes collaboration with Hanmi led the alliances.
You may also be interested in...
Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
Bristol agreed to pay $350m upfront for global rights to Five Prime’s CSF1R antibody program, including FPA008, in a deal that builds on the companies’ previous clinical collaboration agreement.
Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2020
Device financing totaled $1.4bn during the first quarter of 2020. Merger and acquisition activity reached $714.5m, with only two transactions hitting the six-figure mark. Financings by diagnostics/research players totaled $985m and just six companies were acquired, four of which together were valued at $11.6bn, most coming from Thermo Fisher Scientific’s $11.5bn buy of fellow public life sciences company Qiagen NV.
Deals In Depth: May 2020
Repare Therapeutics and Bristol Myers Squibb announced a multi-target discovery collaboration potentially worth over $3bn. Alexion Pharmaceuticals entered into a definitive agreement to acquire fellow public biotech Portola Pharmaceuticals $1.44bn. An increase in both follow-on public offerings and PIPE financings boosted biopharma financing significantly from last month.
Need a specific report? 1000+ reports available
Buy Reports